Drug Trial Radar · NCT03474107
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Last checked: Nov 19, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
608
Actual
Start
Jun 27, 2018
Primary completion
Jul 15, 2020
Study completion Nov 27, 2025
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- Collaborators
- Seagen Inc.
- First posted
- Mar 22, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to compare the overall survival (OS) of participants with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV) to the OS of participants treated with chemotherapy. This study compared progression-free survival on study therapy (PFS1); the overall response rate (ORR) and the disease control rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 of participants treated with EV to participants treated with chemotherapy. In addition, this study evaluated the duration of response (DOR) per RECIST V1.1 of EV and chemotherapy and assessed the safety and tolerability of EV, as well as, the quality of life (QOL) and Patient Reported Outcomes (PRO) parameters.
Conditions
- Ureteral Cancer
- Urothelial Cancer
- Bladder Cancer
Interventions
Enfortumab VedotinDrug
Intravenous infusion
DocetaxelDrug
Intravenous infusion
VinflunineDrug
Intravenous infusion
PaclitaxelDrug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)
Locations
158 sites in 19 countries. Site status is shown where the registry gives one.
UCI Chao Family Comprehensive Cancer Center
Orange, California
University of California
Sacramento, California
Innovative Clinical Research
Whittier, California
University of Colorado
Denver, Colorado
Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut
Sylvester Comprehensive Cancer Center
Miami, Florida
Florida Hospital
Orlando, Florida
Rush University Medical Center
Chicago, Illinois
Norton Cancer Institute
Louisville, Kentucky
Dana-Farber Cancer Institute
Boston, Massachusetts
Nebraska Cancer Specialists
Omaha, Nebraska
Roswell Park Cancer Institute
Buffalo, New York
Long Island Jewish Medical Center
Lake Success, New York
Sidney Kimmel Center for Prostate and Urologic Cancers
New York, New York
Montefiore Medical Center
The Bronx, New York
White Plains Hospital Center for Cancer Care - Oncology Site
White Plains, New York
Toledo Clinic Cancer Center
Toledo, Ohio
Providence Portland Med Center
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Lifespan Rhode Island Hospital
Providence, Rhode Island
Saint Francis Hospital
Greenville, South Carolina
HOPE Cancer Center of East Texas
Tyler, Texas
Benaroya Research Institute at Virginia Mason
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Site AR54001
Buenos Aires, Argentina
Site AU61006
Adelaide, Australia
Site AU61001
Miranda, Australia
Site AU61004
St Leonards, Australia
Site AU61002
Sydney, Australia
Site AT43005
Linz, Austria
Site AT43001
Salzburg, Austria
Site AT43004
Vienna, Austria
Site BE32011
Aalst, Belgium
Site BE32007
Brussels, Belgium
Site BE32013
Brussels, Belgium
Site BE32010
Charleroi, Belgium
Site BE32001
Ghent, Belgium
Site BE32008
Ghent, Belgium
Site BE32005
Hasselt, Belgium
Showing 40 of 158 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.